Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-10T17:28:16.420Z Has data issue: false hasContentIssue false

Is this a non-inferiority trial?

Published online by Cambridge University Press:  02 January 2018

Peter O'Halloran*
Affiliation:
Queen's University Belfast, UK. Email: p.ohalloran@qub.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2013 

Crawford et al Reference Crawford, Thana, Methuen, Ghosh, Stanley and Ross1 have set out to investigate whether screening for suicidal ideation among people who attend primary care services and have signs of depression increases the short-term incidence of feeling that life is not worth living. It seems to me that this is a non-inferiority trial, i.e. the authors want to show that screening is no worse than not screening. This raises a number of design issues.

First, the trial is powered to detect an increase in the proportion who felt their life was not worth living from 30% to 45%. This seems a clinically large increase and suggests that anything short of a 50% increase in relative risk is acceptable. Second, having calculated the sample size based on relative risk, they analyse the main results using odds ratios rather than relative risk, so that it is difficult to see what sort of increase in relative risk was found and impossible to see the confidence interval around the relative risk. Third, if this is seen as a non-inferiority trial, arguably screening would be regarded as non-inferior provided that the possibility of the suicidal ideation rate being 50% worse than non-screening could be ruled out (in the sense that the 95% confidence interval for the difference in ideation rates would not include 50% inferiority relative to the non-screened group). Reference Pocock2 We only have the confidence interval around the odds ratio to go on, but given how wide that is, it is highly likely that the confidence interval would include the 50% increase in relative risk. For these reasons I think the results should be treated with caution.

References

1 Crawford, MJ Thana, L Methuen, C Ghosh, P Stanley, SV Ross, J et al. Impact of screening for risk of suicide: randomised controlled trial. Br J Psychiatry 2011; 198: 379–84.Google Scholar
2 Pocock, SJ. The pros and cons of noninferiority trials. Fund Clin Pharmacol 2003; 17: 483–90.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.